Literature DB >> 18046025

In defense of pharmacoepidemiology--embracing the yin and yang of drug research.

Jerry Avorn1.   

Abstract

Mesh：

Year:  2007        PMID： 18046025     DOI： 10.1056/NEJMp0706892

Source DB:  PubMed          Journal:  N Engl J Med        ISSN： 0028-4793            Impact factor:   91.245


× No keyword cloud information.
  51 in total

1.  Early steps in the development of a claims-based targeted healthcare safety monitoring system and application to three empirical examples.

Authors:  Peter M Wahl; Joshua J Gagne; Thomas E Wasser; Debra F Eisenberg; J Keith Rodgers; Gregory W Daniel; Marcus Wilson; Sebastian Schneeweiss; Jeremy A Rassen; Amanda R Patrick; Jerry Avorn; Rhonda L Bohn
Journal:  Drug Saf       Date:  2012-05-01       Impact factor: 5.606

2.  The value of observational cohort studies for cancer drugs.

Authors:  David R Spigel
Journal:  Biotechnol Healthc       Date:  2010

3.  Registration of observational studies: is it time?

Authors:  Rebecca J Williams; Tony Tse; William R Harlan; Deborah A Zarin
Journal:  CMAJ       Date:  2010-07-19       Impact factor: 8.262

4.  Costs and benefits of free medications after myocardial infarction.

Authors:  Irfan A Dhalla; Monique A Smith; Niteesh K Choudhry; Avram E Denburg
Journal:  Healthc Policy       Date:  2009-11

5.  Medicine. Moving toward transparency of clinical trials.

Authors:  Deborah A Zarin; Tony Tse
Journal:  Science       Date:  2008-03-07       Impact factor: 47.728

6.  Point-counterpoint. The triumph of the null hypothesis: epidemiology in an age of change.

Authors:  Wasim Maziak
Journal:  Int J Epidemiol       Date:  2008-12-17       Impact factor: 7.196

7.  Clinical service of Chinese medicine.

Authors:  Ke-ji Chen
Journal:  Chin J Integr Med       Date:  2008-10-14       Impact factor: 1.978

Review 8.  Desideratum for evidence based epidemiology.

Authors:  J Marc Overhage; Patrick B Ryan; Martijn J Schuemie; Paul E Stang
Journal:  Drug Saf       Date:  2013-10       Impact factor: 5.606

9.  Effectiveness of risedronate and alendronate on nonvertebral fractures: an observational study through 2 years of therapy.

Authors:  R Lindsay; N B Watts; J L Lange; P D Delmas; S L Silverman
Journal:  Osteoporos Int       Date:  2013-04-24       Impact factor: 4.507

10.  Vitamin D in chronic kidney disease: is the jury in?

Authors:  Ian H de Boer; Bryan Kestenbaum
Journal:  Kidney Int       Date:  2008-10       Impact factor: 10.612
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.